Dear Sir, Certainly the management of Type 2 (non-insulin-dependent) diabetes, the "other diabetes", is one of the major and most frustrating problems in medicine today. We still do not know the nature of the underlying hereditary defects. The pioneer prospective University Group Diabetes Project of the 1960s, designed to study the natural history and optimal management of Type 2 diabetes, left many questions unanswered. Therefore, the first report of the UK Multi-Centre study [1] is of interest. With the support of an Oxford research fund, eight pharmaceutical companies, two charitable trusts, and a number of industries, it is planned to study the response to therapy of 3 500 patients. Much care has gone into the design with respect to selection of patients, methods of randomization at various stages, and into ensuring that each therapeutic agent is used optimally. There is need for a well-designed, impartial study, but does this one qualify?
There are two aspects of the study which should be kept in mind when evaluating conclusions regarding optimal therapy that may emerge from the study. These are: (1) the limitations of design for the control group against which the success of the treatment with insulin or with sulphonylurea or biguanide will be measured; (2) the limited degree to which the individual patients will be characterized, since Type 2 diabetes is a heterogeneous disorder.
There is no mention of physical activity in the protocol. The patients randomized to the control group have been advised to take a 'prudent' diet, containing 50% carbohydrate, 'decreased' saturated fat and 'moderately increased' fibre content. Total energy content has been modified in order to obtain 'ideal' body weight. They are seen monthly at first and then every 3 months. However, change in the level of physical activity may be as important as change in diet in the increased incidence of diabetes. As West has stressed, Type 2 diabetes is, to a large degree, a disorder associated with Westernization of food and of energy expenditure, which brings out diabetes in those genetically susceptible [2] . It is true that there are no large scale studies showing efficacy or feasibility of exercise and change of lifestyle as an adjunct to a programme of rehabilitation in Type 2 diabetes, but a total rehabilitative approach warrants consideration. The Stamlers's Chicago intervention trial for risk factors of cardiovascular disease has at least shown that increased physical activity in addition to sustained weight loss can be maintained over a 5-year period [3] . Patients with Type 2 diabetes tend to have a low state of physical training [4] and, even in normal subjects, VO2 max correlates closely with carbohydrate disposal [5] . A programme of exercise added to a dietary regimen can carry additional metabolic and emotional benefits [6] . Two symposia have been devoted to the role of exercise in the management of diabetes [7, 8] , and the subject has been reviewed very recently [91.
The patients in the UK study [1] to date have been characterized by age, weight, fasting blood glucose and routine blood studies. Mean weights have been brought to so-called 'ideal' standards, but the variation around the mean is not given. There has been marked heterogeneity of response to initial dietary management and to the various regimens, but data will not be available to indicate whether particular subgroups of patients may have responded in a particular way. A data base including family history of related disease, course of any obesity, body composition and distribution of body fat, state of physical training, and, in particular, insulin response, both fasting and under stimulus, might aid such identification.
These two considerations suggest that serious misinterpretation could result from the study as designed. We have learned that the oral agents will not work without attention to diet [10] and exercise. Since the control group are merely advised to follow a 'prudent' diet and seen at infrequent intervals, the efficiency of a drng-free therapy could be overlooked because of suboptimal conditions for its use. Conversely, the result of using a particular drug might appear better than that from the prudent diet alone, but in fact the same effect might be obtained by more dedicated use of exercise and dietary control, and at lesser expense.
A stated aim of the study is to determine whether therapy will have 'untoward long-term side effects'. Thus, it is extraordinary to find that there is no mention of how long the study will be extended. Some of the potential vascular complications and the indirect effects of the weight gain (2 kg/year so far) may take years to develop and thus might not be detected.
To confound the results further, smoking habits and the use of anti-hypertensive drugs capable of increasing serum lipid concentrations are not taken into consideration. If subgroups of patients, perhaps differing in insulin secretory capacity or hereditary background, differ in response to a given agent, significant findings may be cancelled out, and the identification both of possible benefits or of contraindications may be obscured.
There is great need for an impartial study, peer-reviewed in its planning, which includes all the main therapeutic options and the potential for evaluating both efficacy and possible long-term adverse effects. Is there a possibility that the organizers of the UK study [1] could incorporate a control group for which aggressive total rehabilitation is stressed and that they could provide an expanded data base for characterization of patients that would aid in identification of important subgroups and their response to the various therapeutic options? 
Insulin internalization in human erythrocytes
Dear Sir, In a recent Letter to the Editor, Bihr et al. [1] concluded from their studies that "(1) insulin binding is not necessarily followed by internalization of insulin; (2) only cells with nuclei internalize insulin; (3) insulin may well exert different effects on intracellular metabolism depending upon nuclei content; and (4) reticulocytes that can internalize insulin might be of importance concerning the rate of insulin degradation in circulating blood."
In contrast with these suggestions, we take the following view. Bihr et al. used electron microscopy to show insulin internalization in blood cells [1] . Prior to this technique, biochemical methods involving receptor down-regulation in vitro pioneered studies of insulin internalization [2] . Unlike electron microscopy, the biochemical methods can evaluate various physiological actions involved in insulin receptor down-regulation and insulin internalization [3] . These biochemical studies are equally important and should be considered simultaneously before arriving at any conclusion from electron microscopic studies of insulin internalization.
The first conclusion by Bihr et al was apparently based upon electron microscopic observations of insulin bound to human erythrocytes. They did not specify the temperature and incubation time for insulin binding prior to the observation.
However, binding is similar at 0 ~ and 4 ~ for both nucleated cells [4] and human erythrocytes. We have shown that 91% 98% of bound insulin at 4 ~ is extractable and the extractable insulin is intact [5] . At 15 ~ after 3.5 h of binding, 80% of bound insulin is extractable and 60% of the extractable insulin is intact, while at 37 ~ with increasing time of incubation, the extractability of cell-bound insulin and the proportion of intact, undegraded, extractable insulin decreases. Since the degradation of insulin in these erythrocytes can only be by cytosolic enzyme [7] , degradation is a measure of internalization. Thus, these findings clearly show that insulin internalization is time-and temperature-dependent in human erythrocytes.
In contrast with the second conclusion of Bihr et al. [1] , our published data [5] [6] [7] [8] provided the following evidence of insulin internalization by human erythrocytes at 37~ (a) human erythrocyte cell membranes lack an insulin degrading enzyme [6] ; (b) there is a very specific and potent insulin degrading enzyme in cell cytosol (7.8); (c) there is a time-dependent continuous increase in insulin association with the cells at 37 ~ [6] ; and (d) about 56% of the cell-associated insulin is degraded at the end of 5 h of incubation at 37 ~ [6] . Moreover, according to biochemical studies performed to evaluate insulin receptor down-regulation (and thereby assess insulin internalization) in 1M-9 lymphocytes (nucleated cells), contradictory results were obtained by Baldwin et al. [9] , that is, insulin internalization was not observed.
Reticulocytes are known not to have nuclei. They are capable of limited protein synthesis due to performed mRNA, although they cannot synthesize mRNA [10] . Thus, Bihr et al. should not have seen insulin internalization in reticulocytes. Therefore, their fourth conclusion is contradictory to their second.
Bihr et al. [1] have drawn their conclusions without referring to the contradictory state of current published reports. We have demonstrated insulin internalization in mature human erythrocytes, which do not possess nuclei. Yours sincerely, S. G. Nerurkar and K. K. Gambhir
